Serum phoenixin-14 shows no association with metabolic syndrome in children with obesity: a cross-sectional study
Frontiers in Pediatrics · 18.08.2026 · 14
DOI: 10.3389/fped.2026.1935719 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Frontiers in Pediatrics, online erschienen am 18.08.2026. Verfasst von Zafer Bağcı und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Konya City Hospital, University of Health Sciences, Konya, Türkiye. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Phoenixin is a novel neuropeptide encoded by the SMIM20 gene, implicated in energy homeostasis and reproduction, but its role in pediatric metabolic syndrome remains unknown.
Methods
This cross-sectional study enrolled 98 children and adolescents aged 7–18 years [45 with Metabolic syndrome (MetS) and 53 with obesity without MetS]. MetS was defined by modified International Diabetes Federation criteria. Biochemical analyses included fasting glucose, lipid profile, and liver enzymes on a Beckman Coulter AU5800 analyzer; insulin, cortisol, adrenocorticotropic hormone (ACTH), thyroid, and reproductive hormones on a Roche Cobas e601 electrochemiluminescence immunoassay system; and HbA1c by high-performance liquid chromatography (Bio-Rad D10). Serum phoenixin-14 was quantified by sandwich ELISA (Bioassay Technology Laboratory Cat. No. E7481Hu; sensitivity 8.19 ng/L; intra-assay CV 6.8%, interassay CV 9.2%). Group comparisons were performed using Mann–Whitney U and chi-square tests; a general linear model (GLM) adjusting for age and Tanner stage assessed the independent effect of the MetS and obese groups on serum phoenixin-14.
Results
Serum phoenixin-14 did not differ between the MetS and obese groups (519.75 ± 196.67 vs. 567.86 ± 368.40 pg/mL; p = 0.955). After adjustment for age and Tanner stage by GLM ( n = 95), the difference remained non-significant (adjusted difference: −26.5 pg/mL, 95% CI: −152.1 to 99.1; p = 0.676; adjusted means: MetS 529.1 pg/mL vs. Obese 555.7 pg/mL). Tanner stage was a significant covariate ( B = 73.04, p = 0.009). Children with MetS were older (13.62 ± 2.51 vs. 12.19 ± 2.65 years; p = 0.010) and had higher median insulin (30.80 vs. 18.20 µIU/mL; p < 0.001), higher triglycerides (172.04 ± 70.94 vs. 106.68 ± 39.27 mg/dL; p < 0.001), lower high-density lipoprotein-cholesterol (38.56 ± 7.73 vs. 47.02 ± 9.99 mg/dL; p < 0.001), and higher ACTH (28.86 ± 14.12 vs. 22.44 ± 11.86 pg/mL; p = 0.018).
Conclusions
In this cohort, serum phoenixin-14 did not differ between obese children with and without metabolic syndrome after adjusting for age and pubertal stage ( p = 0.676). These findings do not support a discriminative role for phoenixin-14 in pediatric MetS. Further studies including healthy normal-weight controls are needed to determine whether phoenixin-14 concentrations are altered in pediatric obesity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Konya City Hospital, University of Health Sciences, Konya, Türkiye.
- Department of Pediatric Endocrinology, Konya City Hospital, Konya, Türkiye.
- Department of Biochemistry, Konya City Hospital, Konya, Türkiye.
- Department of Biochemistry, Fethiye State Hospital, Muğla, Türkiye.
Zitieren
APA
Bağcı, Z., Uyanık, R., Can, Ü., Yılmaz, D., & Akdu, S. (2026). Serum phoenixin-14 shows no association with metabolic syndrome in children with obesity: a cross-sectional study. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1935719
Vancouver
Bağcı Z, Uyanık R, Can Ü, Yılmaz D, Akdu S. Serum phoenixin-14 shows no association with metabolic syndrome in children with obesity: a cross-sectional study. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1935719
BibTeX
@article{Bac2026,
author = {Bağcı, Zafer and Uyanık, Rukiye and Can, Ümmügülsüm and Yılmaz, Deniz and Akdu, Sadinaz},
title = {Serum phoenixin-14 shows no association with metabolic syndrome in children with obesity: a cross-sectional study},
journal = {Frontiers in Pediatrics},
year = {2026},
volume = {14},
doi = {10.3389/fped.2026.1935719}
}
EUVIMED